Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN022150 + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Jiangxi Kvvit Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
DN022150 + AG is an investigational combination therapy being evaluated for the first-line treatment of locally advanced or metastatic pancreatic cancer harboring KRAS G12D mutations. The regimen consists of DN022150, a targeted small molecule inhibitor of the KRAS G12D mutant protein, and "AG," which is the standard-of-care chemotherapy combination of nab-paclitaxel (Abraxane) and gemcitabine. DN022150 is developed by Jiangxi Kvvit Pharmaceutical Co., Ltd. and specifically targets the oncogenic signaling driven by the KRAS G12D mutation, a common driver in pancreatic ductal adenocarcinoma (PDAC). By combining a mutation-specific inhibitor with cytotoxic chemotherapy, the regimen aims to provide synergistic anti-tumor activity, potentially improving outcomes for patients with this difficult-to-treat molecular subtype of pancreatic cancer.
- Brand names
- AbraxaneGemzar
- Other names
- DN022150 + AGDN022150 + Abraxane + Gemcitabine
02
Targets
DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on DN022150 + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DN022150 + nab-paclitaxel + gemcitabine.